ABSTRACT
INTRODUCTION: Cystic fibrosis (CF)-associated liver disease can significantly affect the quality of life and survival of people with CF. The hepatobiliary manifestations in CF are various, with focal/multilobular biliary cirrhosis more common in children and porto-sinusoidal vascular disease (PSVD) in young adults. Portal hypertensive complications, particularly bleeding from esophagogastric varices and hypersplenism are common, while liver failure is rarer and mainly linked to biliary disease. AREAS COVERED: This review explores current therapeutic options for CF-associated liver disease, presenting ongoing studies and new insights into parthenogenesis for potential future therapies. EXPERT OPINION: Monitoring for signs of portal hypertension is essential. Limited evidence supports ursodeoxycholic acid (UDCA) efficacy in halting CF liver disease progression. The effect of cystic fibrosis transmembrane conductance regulator (CFTR) modulators on liver outcomes lacks definitive data, since patients with CF-related liver disease were excluded from trials due to potential hepatotoxicity. A proposed approach involves using UDCA and modulators in early stages, along with anti-inflammatory agents, with further therapeutic strategies awaiting randomized trials. Prevention of portal hypertensive bleeding includes endoscopic sclerotherapy or ligation of esophageal varices. Nonselective beta-blockers may also prevent bleeding and could be cautiously implemented. Other non-etiological treatments require investigation.
Subject(s)
Cystic Fibrosis , Hypertension, Portal , Humans , Hypertension, Portal/physiopathology , Hypertension, Portal/drug therapy , Hypertension, Portal/etiology , Cystic Fibrosis/complications , Cystic Fibrosis/physiopathology , Cystic Fibrosis/drug therapy , Ursodeoxycholic Acid/therapeutic use , Liver Diseases/physiopathology , Liver Diseases/therapy , Liver Diseases/drug therapy , Esophageal and Gastric Varices/etiology , Esophageal and Gastric Varices/therapy , Esophageal and Gastric Varices/physiopathology , Cystic Fibrosis Transmembrane Conductance Regulator/genetics , Cystic Fibrosis Transmembrane Conductance Regulator/metabolism , Quality of Life , Disease ProgressionABSTRACT
BACKGROUND: Portal hypertension affects hepatic, splanchnic and portosystemic collateral systems. Although alcohol is a well-known risk factor for liver cirrhosis, it also affects vascular contractility. However, the relevant effects on portal hypertension have not been evaluated in non-alcoholic cirrhosis. The present study aimed to investigate the impacts of low-dose alcohol on portal hypertension-related derangements in non-alcoholic cirrhotic rats. METHODS: Sprague-Dawley rats received bile duct ligation to induce cirrhosis or sham operation as controls. The chronic or acute effects of low-dose alcohol (2.4 g/kg/day, oral gavage, approximately 1.3 drinks/day in humans) were evaluated. RESULTS: The chronic administration of low-dose alcohol did not precipitate liver fibrosis in the sham or cirrhotic rats; however, it significantly increased splanchnic blood inflow (P=0.034) and portosystemic collaterals (P=0.001). Mesenteric angiogenesis and pro-angiogenic proteins were up-regulated in the alcohol-treated cirrhotic rats, and poorer collateral vasoresponsiveness to vasoconstrictors (P<0.001) was noted. Consistently, acute alcohol administration reduced splenorenal shunt resistance. Collateral vasoresponsiveness to vasoconstrictors also significantly decreased (P=0.003). CONCLUSIONS: In non-alcoholic cirrhosis rats, a single dose of alcohol adversely affected portosystemic collateral vessels due to vasodilatation. Long-term alcohol use precipitated splanchnic hyperdynamic circulation, in which mesenteric angiogenesis played a role. Further studies are warranted to evaluate the benefits of avoiding low-dose alcohol consumption in patients with non-alcoholic cirrhosis.
Subject(s)
Ethanol , Hypertension, Portal , Liver Cirrhosis , Rats, Sprague-Dawley , Splanchnic Circulation , Animals , Ethanol/administration & dosage , Male , Rats , Splanchnic Circulation/drug effects , Liver Cirrhosis/physiopathology , Liver Cirrhosis/chemically induced , Liver Cirrhosis/pathology , Hypertension, Portal/physiopathology , Hypertension, Portal/etiology , Hypertension, Portal/chemically induced , Hypertension, Portal/pathology , Collateral Circulation/drug effects , Vasoconstriction/drug effectsSubject(s)
Ascites , Hypertension, Portal , Myositis , Humans , Ascites/etiology , Ascites/diagnosis , Hypertension, Portal/diagnosis , Hypertension, Portal/etiology , Hypertension, Portal/physiopathology , Myositis/diagnosis , Myositis/complications , Myositis/immunology , Treatment Outcome , Female , Middle Aged , Male , AdultABSTRACT
This article reviews the pathophysiology of portal hypertension that includes multiple mechanisms internal and external to the liver. This article starts with a review of literature describing the cellular and molecular mechanisms of portal hypertension, microvascular thrombosis, sinusoidal venous congestion, portal angiogenesis, vascular hypocontractility, and hyperdynamic circulation. Mechanotransduction and the gut-liver axis, which are newer areas of research, are reviewed. Dysfunction of this axis contributes to chronic liver injury, inflammation, fibrosis, and portal hypertension. Sequelae of portal hypertension are discussed in subsequent studies.
Subject(s)
Hypertension, Portal , Hypertension, Portal/physiopathology , Hypertension, Portal/etiology , Humans , Mechanotransduction, Cellular , Liver Cirrhosis/physiopathology , Liver Cirrhosis/complications , Liver/physiopathology , Liver/blood supply , Neovascularization, Pathologic/physiopathology , Liver Circulation/physiology , Portal Vein/physiopathologyABSTRACT
Measurement of hepatic venous pressure gradient (HVPG) effectively mirrors the severity of portal hypertension (PH) and offers valuable insights into prognosis of liver disease, including the risk of decompensation and mortality. Additionally, HVPG offers crucial information about treatment response to nonselective beta-blockers and other medications, with its utility demonstrated in clinical trials in patients with PH. Despite the widespread dissemination and validation of noninvasive tests, HVPG still holds a significant role in hepatology. Physicians treating patients with liver diseases should comprehend the HVPG measurement procedure, its applications, and how to interpret the results and potential pitfalls.
Subject(s)
Hypertension, Portal , Portal Pressure , Humans , Hypertension, Portal/physiopathology , Hypertension, Portal/diagnosis , Hepatic Veins/physiopathology , Prognosis , Severity of Illness IndexABSTRACT
Portopulmonary hypertension (POPH), hepatopulmonary syndrome, and hepatic hydrothorax constitute significant complications of portal hypertension, with important implications for management and liver transplantation (LT) candidacy. POPH is characterized by obstruction and remodeling of the pulmonary resistance arterial bed. Hepatopulmonary syndrome is the most common pulmonary vascular disorder, characterized by intrapulmonary vascular dilatations causing impaired gas exchange. LT may improve prognosis in select patients with POPH. LT is the only effective treatment of hepatopulmonary syndrome. Hepatic hydrothorax is defined as transudative pleural fluid accumulation that is not explained by primary cardiopulmonary or pleural disease. LT is the definitive cure for hepatic hydrothorax.
Subject(s)
Hepatopulmonary Syndrome , Hydrothorax , Hypertension, Portal , Hypertension, Pulmonary , Liver Transplantation , Humans , Hypertension, Portal/etiology , Hypertension, Portal/complications , Hypertension, Portal/physiopathology , Hepatopulmonary Syndrome/etiology , Hepatopulmonary Syndrome/physiopathology , Hepatopulmonary Syndrome/therapy , Hydrothorax/etiology , Hydrothorax/therapy , Hypertension, Pulmonary/etiology , Hypertension, Pulmonary/physiopathologyABSTRACT
The progressive use of noninvasive tests (NITs) has changed the way hepatologists diagnose and manage patients with chronic liver disease, mainly because of their easiness to use and the ability to be repeated during follow-up. Liver stiffness measurement is the NIT with more scientific evidence. NITs have demonstrated to be useful to detect not only liver fibrosis but also the presence of clinically significant portal hypertension. Moreover, current evidence supports they can also be useful to evaluate the prognosis of patients with chronic liver disease.
Subject(s)
Elasticity Imaging Techniques , Hypertension, Portal , Liver Cirrhosis , Humans , Hypertension, Portal/diagnosis , Hypertension, Portal/etiology , Hypertension, Portal/physiopathology , Liver Cirrhosis/diagnosis , Liver Cirrhosis/complications , Liver Cirrhosis/physiopathology , Liver/diagnostic imaging , Liver/pathology , Liver/physiopathology , Prognosis , Esophageal and Gastric Varices/diagnosis , Esophageal and Gastric Varices/etiologyABSTRACT
Portal hypertension is the key mechanism driving the transition from compensated to decompensated cirrhosis. In this review, the authors described the pathophysiology of portal hypertension in cirrhosis and the rationale of pharmacologic treatment of portal hypertension. We discussed both etiologic and nonetiologic treatment of portal hypertension and the specific clinical scenarios how nonselective beta-blocker can be used in patients with cirrhosis. Finally, the authors summarized the evidence for emerging alternatives for portal hypertension in patients with cirrhosis.
Subject(s)
Adrenergic beta-Antagonists , Hypertension, Portal , Liver Cirrhosis , Hypertension, Portal/drug therapy , Hypertension, Portal/physiopathology , Hypertension, Portal/etiology , Humans , Adrenergic beta-Antagonists/therapeutic use , Liver Cirrhosis/drug therapy , Liver Cirrhosis/complications , Liver Cirrhosis/physiopathology , Antihypertensive Agents/therapeutic use , Esophageal and Gastric Varices/etiology , Esophageal and Gastric Varices/drug therapyABSTRACT
Acute kidney injury (AKI) is a common complication among patients with decompensated cirrhosis and its development is associated with worse prognosis in terms of survival. Patients with decompensated cirrhosis may develop a unique type of AKI, known as hepatorenal syndrome (HRS-AKI), characterized by marked impairment of kidney function due to haemodynamic changes that occur in late stages of liver cirrhosis. Besides, patients with cirrhosis also may develop chronic alterations of kidney function (chronic kidney disease, CKD), the incidence of which is increasing markedly and may be associated with clinical complications. The aim of this review is to provide the reader with an update of the most relevant aspects of alterations of kidney function in patients with cirrhossi that may be useful for theri clinical practice.
Subject(s)
Acute Kidney Injury , Hepatorenal Syndrome , Hypertension, Portal , Liver Cirrhosis , Humans , Hypertension, Portal/etiology , Hypertension, Portal/physiopathology , Hypertension, Portal/complications , Hepatorenal Syndrome/etiology , Hepatorenal Syndrome/physiopathology , Acute Kidney Injury/etiology , Acute Kidney Injury/physiopathology , Liver Cirrhosis/complications , Liver Cirrhosis/physiopathology , Renal Insufficiency, Chronic/complications , Renal Insufficiency, Chronic/physiopathologyABSTRACT
Portal hypertension has cerebral consequences via its causes and complications, namely hepatic encephalopathy (HE), a common and devastating brain disturbance caused by liver insufficiency and portosystemic shunting. The pathogenesis involves hyperammonemia and systemic inflammation. Symptoms are disturbed personality and reduced attention. HE is minimal or grades I to IV (coma). Bouts of HE are episodic and often recurrent. Initial treatment is of events that precipitated the episode and exclusion of nonhepatic causes. Specific anti-HE treatment is lactulose. By recurrence, rifaximin is add-on. Anti-HE treatment is efficacious also for prophylaxis, but emergence of HE marks advanced liver disease and a dismal prognosis.
Subject(s)
Hepatic Encephalopathy , Hypertension, Portal , Lactulose , Hepatic Encephalopathy/etiology , Hepatic Encephalopathy/physiopathology , Humans , Hypertension, Portal/etiology , Hypertension, Portal/complications , Hypertension, Portal/physiopathology , Lactulose/therapeutic use , Rifaximin/therapeutic use , Gastrointestinal Agents/therapeutic use , Hyperammonemia/etiology , Hyperammonemia/complicationsSubject(s)
Heart Failure , Portasystemic Shunt, Transjugular Intrahepatic , Humans , Portasystemic Shunt, Transjugular Intrahepatic/adverse effects , Heart Failure/etiology , Heart Failure/physiopathology , Heart Failure/surgery , Heart Failure/diagnostic imaging , Treatment Outcome , Male , Middle Aged , Hypertension, Portal/surgery , Hypertension, Portal/etiology , Hypertension, Portal/physiopathology , Hypertension, Portal/diagnostic imaging , FemaleABSTRACT
Managing complications of liver cirrhosis such as varices needing treatment (VNT) and clinically significant portal hypertension (CSPH) demands precise and non-invasive diagnostic methods. This study assesses the efficacy of spleen stiffness measurement (SSM) using a 100-Hz probe for predicting VNT and CSPH, aiming to refine diagnostic thresholds. A retrospective analysis was conducted on 257 cirrhotic patients, comparing the diagnostic performance of SSM against traditional criteria, including Baveno VII, for predicting VNT and CSPH. The DeLong test was used for statistical comparisons among predictive models. The success rate of SSM@100 Hz was 94.60%, and factors related to SSM failure were high body mass index and small spleen volume or length. In our cohort, the identified SSM cut-off of 38.9 kPa, which achieved a sensitivity of 92% and a negative predictive value (NPV) of 98% for detecting VNT, is clinically nearly identical to the established Baveno threshold of 40 kPa. The predictive capability of the SSM-based model for VNT was superior to the LSM ± PLT model (p = 0.017). For CSPH prediction, the SSM model notably outperformed existing non-invasive tests (NITs), with an AUC improvement and significant correlations with HVPG measurements (obtained from 49 patients), highlighting a correlation coefficient of 0.486 (p < 0.001) between SSM and HVPG. Therefore, incorporating SSM into clinical practice significantly enhances the prediction accuracy for both VNT and CSPH in cirrhosis patients, mainly due to the high correlation between SSM and HVPG. SSM@100 Hz can offer valuable clinical assistance in avoiding unnecessary endoscopy in these patients.
Subject(s)
Elasticity Imaging Techniques , Hypertension, Portal , Liver Cirrhosis , Spleen , Humans , Liver Cirrhosis/complications , Liver Cirrhosis/diagnosis , Male , Middle Aged , Female , Spleen/pathology , Hypertension, Portal/diagnosis , Hypertension, Portal/physiopathology , Retrospective Studies , Aged , Elasticity Imaging Techniques/methods , Esophageal and Gastric Varices/diagnosis , Esophageal and Gastric Varices/etiology , AdultABSTRACT
Clinically significant portal hypertension (CSPH) in patients with compensated advanced chronic liver disease indicates an increased risk of decompensation and death. While invasive methods like hepatic venous-portal gradient measurement is considered the gold standard, non-invasive tests (NITs) have emerged as valuable tools for diagnosing and monitoring CSPH. This review comprehensively explores non-invasive diagnostic modalities for portal hypertension, focusing on NITs in the setting of hepatitis B and hepatitis C virus-related cirrhosis. Biochemical-based NITs can be represented by single serum biomarkers (e.g., platelet count) or by composite scores that combine different serum biomarkers with each other or with demographic characteristics (e.g., FIB-4). On the other hand, liver stiffness measurement and spleen stiffness measurement can be assessed using a variety of elastography techniques, and they can be used alone, in combination with, or as a second step after biochemical-based NITs. The incorporation of liver and spleen stiffness measurements, alone or combined with platelet count, into established and validated criteria, such as Baveno VI or Baveno VII criteria, provides useful tools for the prediction of CSPH and for ruling out high-risk varices, potentially avoiding invasive tests like upper endoscopy. Moreover, they have also been shown to be able to predict liver-related events (e.g., the occurrence of hepatic decompensation). When transient elastography is not available or not feasible, biochemical-based NITs (e.g., RESIST criteria, that are based on the combination of platelet count and albumin levels) are valid alternatives for predicting high-risk varices both in patients with untreated viral aetiology and after sustained virological response. Ongoing research should explore novel biomarkers and novel elastography techniques, but current evidence supports the utility of routine blood tests, LSM, and SSM as effective surrogates in diagnosing and staging portal hypertension and predicting patient outcomes.
Subject(s)
Biomarkers , Elasticity Imaging Techniques , Hypertension, Portal , Liver Cirrhosis , Humans , Hypertension, Portal/complications , Hypertension, Portal/physiopathology , Hypertension, Portal/diagnosis , Hypertension, Portal/etiology , Liver Cirrhosis/complications , Liver Cirrhosis/blood , Liver Cirrhosis/diagnosis , Elasticity Imaging Techniques/methods , Biomarkers/blood , Hepatitis B/complications , Hepatitis B/diagnosis , Platelet Count , Hepatitis C/complications , Hepatitis C/diagnosis , Spleen/diagnostic imagingABSTRACT
This is a retrospective study focused on recompensation after transjugular intrahepatic portosystemic shunt (TIPS) procedure. The authors confirmed TIPS could be a treatment for recompensation of patients with cirrhosis according to Baveno VII. The paper identified age and post-TIPS portal pressure gradient as independent predictors of recompensation in patients with decompensated cirrhosis after TIPS. These results need to be validated in a larger prospective cohort.
Subject(s)
Hypertension, Portal , Liver Cirrhosis , Portal Pressure , Portasystemic Shunt, Transjugular Intrahepatic , Portasystemic Shunt, Transjugular Intrahepatic/methods , Humans , Liver Cirrhosis/surgery , Liver Cirrhosis/complications , Retrospective Studies , Hypertension, Portal/surgery , Hypertension, Portal/etiology , Hypertension, Portal/diagnosis , Hypertension, Portal/physiopathology , Treatment Outcome , Middle Aged , Female , Male , Aged , Age Factors , Hepatic Encephalopathy/etiology , Hepatic Encephalopathy/surgeryABSTRACT
PURPOSE OF THIS REVIEW: Aging is a process of physiological slowing, reduced regenerative capacity and inability to maintain cellular homeostasis. World Health Organisation declared the commencement of population aging globally, largely attributed to improvement in the healthcare system with early diagnosis and effective clinical management. Liver ages similar to other organs, with reduction in size and blood flow. In this review we aim to evaluate the effect of aging in liver disease. RECENT FINDINGS: Aging causes dysregulation of major carbohydrate, fat and protein metabolism in the liver. Age is a major risk factor for liver fibrosis accelerated by sinusoidal endothelial dysfunction and immunological disharmony. Age plays a major role in patients with liver cirrhosis and influence outcomes in patients with portal hypertension. Transient elastography may be an useful tool in the assessment of portal hypertension. Hepatic structural distortion, increased vascular resistance, state of chronic inflammation, associated comorbidities, lack of physiological reserve in the older population may aggravate portal hypertension in patients with liver cirrhosis and may result in pronounced variceal bleed. Cut-offs for other non-invasive markers of fibrosis may differ in the elderly population. Non-selective beta blockers initiated at lower dose followed by escalation are the first line of therapy in elderly patients with cirrhosis and portal hypertension, unless contraindicated. Acute variceal bleed in the elderly cirrhotic patients can be life threatening and may cause rapid exsanguination due to poor reserve and associated comorbidities. Vasoactive drugs may be associated with more adverse reactions. Early endoscopy may be warranted in the elderly patients with acute variceal bleed. Role of TIPS in the elderly cirrhotics discussed. Management of portal hypertension in the older population may pose significant challenges to the treating clinician.
Subject(s)
Hypertension, Portal , Liver Cirrhosis , Humans , Hypertension, Portal/diagnosis , Hypertension, Portal/physiopathology , Hypertension, Portal/therapy , Hypertension, Portal/etiology , Liver Cirrhosis/complications , Liver Cirrhosis/physiopathology , Aged , Aging/physiology , Esophageal and Gastric Varices/etiology , Esophageal and Gastric Varices/therapy , Esophageal and Gastric Varices/diagnosisABSTRACT
In recent years, the pathophysiological concept of decompensated liver cirrhosis has undergone significant changes. Until a few years ago, the focus of pathophysiological considerations was on the hyperdynamic circulation resulting from portal hypertension. In recent years, emerging data suggests that increased bacterial translocation leading to systemic inflammation plays an important role in patients with decompensated liver cirrhosis. This inflammation affects a variety of extrahepatic organs. Nowadays, liver cirrhosis is considered not only a condition confined to the liver but rather an inflammatory-triggered multisystem disease. The existing inflammation serves as the common pathophysiological explanation for the diverse impact of liver cirrhosis on several extrahepatic organs. It plays a significant role in the development of conditions such as hepatorenal syndrome, cirrhotic cardiomyopathy, hepatopulmonary syndrome, hepatic encephalopathy, and even in the emergence of cirrhosis-associated relative adrenal insufficiency. These new pathophysiological insights hold clinical significance as they influence the prophylaxis and treatment of patients with decompensated liver cirrhosis.
Subject(s)
Liver Cirrhosis , Humans , Liver Cirrhosis/complications , Liver Cirrhosis/physiopathology , Inflammation , Hypertension, Portal/etiology , Hypertension, Portal/physiopathology , Hypertension, Portal/therapy , Hepatic Encephalopathy/physiopathology , Hepatic Encephalopathy/etiology , Hepatic Encephalopathy/diagnosisABSTRACT
Porto-sinusoidal vascular disorder (PSVD) encompasses a group of vascular disorders characterized by lesions of the portal venules and sinusoids with clinical manifestations ranging from non-specific abnormalities in serum liver enzymes to clinically overt portal hypertension and related complications. Several reports have documented cases of PSVD in patients with systemic autoimmune conditions, such as systemic lupus erythematosus, systemic sclerosis, and rheumatoid arthritis. It is of note that these diseases share specific pathophysiological features with PSVD, including endothelial dysfunction, vascular inflammation, and molecular signatures. This narrative review aims to summarize the current knowledge on the association between PSVD and systemic autoimmune diseases, emphasizing the importance of promptly recognizing this condition in the rheumatological practice, and highlighting the key aspects where further research is necessary from both pathogenic and clinical perspectives.
Subject(s)
Autoimmune Diseases , Humans , Autoimmune Diseases/immunology , Portal Vein , Hypertension, Portal/immunology , Hypertension, Portal/physiopathology , Vascular Diseases/immunology , Scleroderma, Systemic/immunology , Scleroderma, Systemic/complicationsABSTRACT
To investigate the clinical value of contrast-enhanced ultrasound in the prediction of hepatic encephalopathy (HE) in patients with hepatitis B cirrhosis after intrahepatic portal-systemic shunt via jugular vein. In this retrospective study, we collected data from 75 patients with hepatitis B, cirrhosis, and portal hypertension who underwent jugular intrahepatic portosystemic shunt from February 2019 to February 2022. The diagnostic instrument used was the TOSHIBA Aplio500 color Doppler ultrasound with contrast-enhanced ultrasound capabilities. The trial group comprised 20 patients with HE within 3 months postsurgery, while the control group (CG) included 55 patients without HE within the same postoperative period. All patients underwent various examinations before and within 48 hours after surgery, including observation of liver and spleen size and stent position, as well as assessment of blood flow direction in portal and hepatic veins. Subsequently, contrast-enhanced ultrasound was employed to examine and observe perfusion changes of contrast agents in hepatic veins, hepatic arteries, and portal veins (PV). Changes in PV pressure gradient, intrahepatic, and stent blood flow perfusion (BFP) were explored in both postoperative trials and CGs. The trial group exhibited higher BFP volume, PV pressure gradient difference, and percentage decrease compared to the CG. A weak positive correlation was observed between blood flow within the liver stent and PV pressure gradient difference, as well as the percentage decrease in PV pressure gradient. The correlation coefficient between blood flowing perfusion volume within the stent and the difference in PV pressure gradient was Râ =â 0.415 (Pâ =â .000). The correlating coefficient between BFP amount within the stent and the percentage decrease in PV pressure gradient was Râ =â 0.261 (Pâ =â .027). The area under the receiver operating characteristic curve for stent perfusion volume, difference in PV pressure gradient, and percentage decrease in PV pressure gradient was 0.691, 0.759, and 0.742, respectively. An increase in PV pressure gradient accelerates blood flow within the stent, predisposing to HE. Changes in hepatic BFP following transjugular intrahepatic portosystemic shunt can effectively predict the occurrence of HE, demonstrating significant clinical relevance.